Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,deferredLongTermLiab,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,marketState,currency,exchange,shortName,market,priceHint,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsTrailingTwelveMonths,epsForward,exchangeDataDelayedBy,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Apr 14, 2021) 4","Short Ratio (Apr 14, 2021) 4","Short % of Float (Apr 14, 2021) 4","Short % of Shares Outstanding (Apr 14, 2021) 4","Shares Short (prior month Mar 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,CYAD,-4636000,15005200,5190500,,-303500,,-303500,2263000,0,-6065000,-6065000,-1388500,-102000,,,,0,0,6065000,0,5761500,,-303500,-303500,34747000,43349000,35090000,30994000,541000,4013000,66084000,48513000,220000,-91826000,20731000,883000,30958000,6630000,17234000,11834000,37000,30958000,4119000,19705000,907000,4736000,-424000,53500,-340500,1733500,-4729000,500,-6516000,431500,59000,-451000,2074000,-5810000,-39000,7871000,en-US,US,EQUITY,True,Nasdaq Real Time Price,REGULAR,USD,NGM,Celyad Oncology SA,us_market,4,NasdaqGM,Celyad Oncology SA,EUR,43690,18200,0.6099999,0.16223401,3.76 - 10.325,-5.955,-0.57675546,3.76,10.325,-1.488,-4.07,0,2.223,4.2644444,0.105555534,0.024752472,5.869884,-1.4998841,-0.25552192,67555392,-1.07371,1.9658118,15,America/New_York,EDT,-14400000,False,False,0.0,4.37 - 4.37,4.37,4.34,4.53,8,8,finmb_34816993,4.37,1630503002,0.0,4.48,4.37,4.37,136,1.49,,,10.325,3.76,4.2644,5.8699,43.69k,18.2k,15.01M,,11.83M,0.00%,7.06%,210.9k,13.06,,1.48%,210.28k,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,"-524,800.00%",-21.04%,-44.91%,5k,0.00,-100.00%,5k,-25.6M,-17.2M,-1.4880,,17.23M,1.21,3.64M,11.74,1.66,2.22,-27.66M,-11.11M,Value,1435,Healthcare,87,"Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T (CAR-T) cell-based therapies for the treatment of cancer. Its lead product candidates includes CYAD-101, an allogeneic CAR-T candidate that is in Phase 1 clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T therapy that is in Phase 1 clinical trial for the treatment of hematological malignancies and solid tumors. The company's preclinical candidates, include allogeneic CAR-T candidate for the treatment of solid tumors; CYAD-221, shRNA based allogeneic CAR-T candidate to treat B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting natural killer group 2D ligands (NKG2D) and an undisclosed membrane protein. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.",Mont-Saint-Guibert,32 1 039 41 00,1609372800,Belgium,http://www.celyad.com,86400,Axis Business Park,32 1 039 41 41,Biotechnology,Rue Edouard Belin 2
t-1,CYAD,-4636000,15005200,5190500,,-303500,,-303500,2263000,0,-6065000,-6065000,-1388500,-102000,,,,0,0,6065000,0,5761500,,-303500,-303500,34747000,43349000,35090000,30994000,541000,4013000,66084000,48513000,220000,-91826000,20731000,883000,30958000,6630000,17234000,11834000,37000,30958000,4119000,19705000,907000,4736000,-424000,53500,-340500,1733500,-4729000,500,-6516000,431500,59000,-451000,2074000,-5810000,-39000,7871000,en-US,US,EQUITY,True,Nasdaq Real Time Price,REGULAR,USD,NGM,Celyad Oncology SA,us_market,4,NasdaqGM,Celyad Oncology SA,EUR,43690,18200,0.6099999,0.16223401,3.76 - 10.325,-5.955,-0.57675546,3.76,10.325,-1.488,-4.07,0,2.223,4.2644444,0.105555534,0.024752472,5.869884,-1.4998841,-0.25552192,67555392,-1.07371,1.9658118,15,America/New_York,EDT,-14400000,False,False,0.0,4.37 - 4.37,4.37,4.34,4.53,8,8,finmb_34816993,4.37,1630503002,0.0,4.48,4.37,4.37,136,1.49,,,10.325,3.76,4.2644,5.8699,43.69k,18.2k,15.01M,,11.83M,0.00%,7.06%,210.9k,13.06,,1.48%,210.28k,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,"-524,800.00%",-21.04%,-44.91%,5k,0.00,-100.00%,5k,-25.6M,-17.2M,-1.4880,,17.23M,1.21,3.64M,11.74,1.66,2.22,-27.66M,-11.11M,Value,1435,Healthcare,87,"Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T (CAR-T) cell-based therapies for the treatment of cancer. Its lead product candidates includes CYAD-101, an allogeneic CAR-T candidate that is in Phase 1 clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T therapy that is in Phase 1 clinical trial for the treatment of hematological malignancies and solid tumors. The company's preclinical candidates, include allogeneic CAR-T candidate for the treatment of solid tumors; CYAD-221, shRNA based allogeneic CAR-T candidate to treat B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting natural killer group 2D ligands (NKG2D) and an undisclosed membrane protein. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.",Mont-Saint-Guibert,32 1 039 41 00,1609372800,Belgium,http://www.celyad.com,86400,Axis Business Park,32 1 039 41 41,Biotechnology,Rue Edouard Belin 2
t-2,CYAD,-5215000,15005200,5570500,,-8298500,,-8298500,2394500,2500,-7055000,-7055000,-907500,-77000,,,,0,2500,7057500,0,-1243500,,-8298500,-8298500,34650000,43349000,45442000,30318000,573000,2176000,75760000,48513000,260000,-91021000,32135000,883000,29477000,6557000,26692000,10798000,91000,29477000,4231000,29439000,2123000,5782000,-439000,25000,-383000,964500,-6323000,3500,-7316500,443500,61500,-123000,1347500,1100500,-36000,18641000,en-US,US,EQUITY,True,Nasdaq Real Time Price,REGULAR,USD,NGM,Celyad Oncology SA,us_market,4,NasdaqGM,Celyad Oncology SA,EUR,43690,18200,0.6099999,0.16223401,3.76 - 10.325,-5.955,-0.57675546,3.76,10.325,-1.488,-4.07,0,2.223,4.2644444,0.105555534,0.024752472,5.869884,-1.4998841,-0.25552192,67555392,-1.07371,1.9658118,15,America/New_York,EDT,-14400000,False,False,0.0,4.37 - 4.37,4.37,4.34,4.53,8,8,finmb_34816993,4.37,1630503002,0.0,4.48,4.37,4.37,136,1.49,,,10.325,3.76,4.2644,5.8699,43.69k,18.2k,15.01M,,11.83M,0.00%,7.06%,210.9k,13.06,,1.48%,210.28k,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,"-524,800.00%",-21.04%,-44.91%,5k,0.00,-100.00%,5k,-25.6M,-17.2M,-1.4880,,17.23M,1.21,3.64M,11.74,1.66,2.22,-27.66M,-11.11M,Value,1435,Healthcare,87,"Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T (CAR-T) cell-based therapies for the treatment of cancer. Its lead product candidates includes CYAD-101, an allogeneic CAR-T candidate that is in Phase 1 clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T therapy that is in Phase 1 clinical trial for the treatment of hematological malignancies and solid tumors. The company's preclinical candidates, include allogeneic CAR-T candidate for the treatment of solid tumors; CYAD-221, shRNA based allogeneic CAR-T candidate to treat B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting natural killer group 2D ligands (NKG2D) and an undisclosed membrane protein. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.",Mont-Saint-Guibert,32 1 039 41 00,1609372800,Belgium,http://www.celyad.com,86400,Axis Business Park,32 1 039 41 41,Biotechnology,Rue Edouard Belin 2
t-3,CYAD,-5215000,15005200,5570500,,-8298500,,-8298500,2394500,2500,-7055000,-7055000,-907500,-77000,,,,0,2500,7057500,0,-1243500,,-8298500,-8298500,34650000,43349000,45442000,30318000,573000,2176000,75760000,48513000,260000,-91021000,32135000,883000,29477000,6557000,26692000,10798000,91000,29477000,4231000,29439000,2123000,5782000,-439000,25000,-383000,964500,-6323000,3500,-7316500,443500,61500,-123000,1347500,1100500,-36000,18641000,en-US,US,EQUITY,True,Nasdaq Real Time Price,REGULAR,USD,NGM,Celyad Oncology SA,us_market,4,NasdaqGM,Celyad Oncology SA,EUR,43690,18200,0.6099999,0.16223401,3.76 - 10.325,-5.955,-0.57675546,3.76,10.325,-1.488,-4.07,0,2.223,4.2644444,0.105555534,0.024752472,5.869884,-1.4998841,-0.25552192,67555392,-1.07371,1.9658118,15,America/New_York,EDT,-14400000,False,False,0.0,4.37 - 4.37,4.37,4.34,4.53,8,8,finmb_34816993,4.37,1630503002,0.0,4.48,4.37,4.37,136,1.49,,,10.325,3.76,4.2644,5.8699,43.69k,18.2k,15.01M,,11.83M,0.00%,7.06%,210.9k,13.06,,1.48%,210.28k,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,"-524,800.00%",-21.04%,-44.91%,5k,0.00,-100.00%,5k,-25.6M,-17.2M,-1.4880,,17.23M,1.21,3.64M,11.74,1.66,2.22,-27.66M,-11.11M,Value,1435,Healthcare,87,"Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T (CAR-T) cell-based therapies for the treatment of cancer. Its lead product candidates includes CYAD-101, an allogeneic CAR-T candidate that is in Phase 1 clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T therapy that is in Phase 1 clinical trial for the treatment of hematological malignancies and solid tumors. The company's preclinical candidates, include allogeneic CAR-T candidate for the treatment of solid tumors; CYAD-221, shRNA based allogeneic CAR-T candidate to treat B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting natural killer group 2D ligands (NKG2D) and an undisclosed membrane protein. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.",Mont-Saint-Guibert,32 1 039 41 00,1609372800,Belgium,http://www.celyad.com,86400,Axis Business Park,32 1 039 41 41,Biotechnology,Rue Edouard Belin 2
